Priovant Therapeutics, a Roivant Sciences subsidiary, reported that brepocitinib—a dual JAK1/TYK2 inhibitor licensed from Pfizer—met endpoints in a proof‑of‑concept study in cutaneous sarcoidosis. The drug now appears on track for pivotal testing in a rare inflammatory skin disorder with no FDA‑approved treatments. The program shift accelerates Roivant’s rare‑disease footprint and positions brepocitinib for potential blockbuster status if larger trials confirm efficacy and safety. The outcome also illustrates how biotech licensing from major pharmas can resurface assets into high‑value orphan indications.